Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer

Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer

Abstract Objective Cemiplimab, a novel PD-1 inhibitor, exhibits significant antitumor activity against advanced non-small cell lung cancer (NSCLC). However, the cost-effectiveness of this drug for the treatment remains unclear. This study aimed to assess the cost-effectiveness of cemiplimab plus che...

Full description

Bibliographic Details
Main Authors:	Yitian Lang, Yan Lin, Meng Deng, Xiaoyan Liu
Format:	Article
Language:	English
Published:	BMC 2024-02-01
Series:	BMC Cancer
Subjects:	Cost-effectiveness Non-small cell lung cancer Cemiplimab plus chemotherapy Partitioned survival approach
Online Access:	https://doi.org/10.1186/s12885-024-11992-6

Similar Items

Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer
by: Xueyan Liang, et al.
Published: (2023-04-01)

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
by: Tingting Lu, et al.
Published: (2023-07-01)

Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis
by: Xueyan Liang, et al.
Published: (2023-02-01)

Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer
by: Josephine Louella Feliciano, et al.
Published: (2023-04-01)

Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis
by: Yan Li, et al.
Published: (2022-09-01)

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer
by: Xueyan Liang, et al.
Published: (2023-01-01)

A Case of sustained complete response of advanced cutaneous Squamous Cell Cancer of the scalp to Cemiplimab
by: Gogo-ogute E. Ibodeng, et al.
Published: (2023-03-01)

Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China
by: Hao Wang, et al.
Published: (2022-12-01)

Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer
by: Hao Wang, et al.
Published: (2023-03-01)

Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients
by: Hanrui Zheng, et al.
Published: (2024-04-01)

Intravascular squamous cell carcinoma treated with cemiplimab
by: Alexander N. Rose, BS, et al.
Published: (2021-08-01)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
by: Xiaomin Wan, et al.
Published: (2021-08-01)

Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis
by: Xiaoyan Liu, et al.
Published: (2021-10-01)

Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced gastric cancer: A cost‐effectiveness analysis
by: Yitian Lang, et al.
Published: (2023-09-01)

Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience
by: Keren Rouvinov, et al.
Published: (2023-11-01)

Effective Management of Nasal Vestibule Squamous Cell Carcinoma with Cemiplimab: A Case Report
by: Ferdinando Costabile, et al.
Published: (2023-09-01)

Advanced Squamous Cell Carcinoma Developed on Chronic Hidradenitis Suppurativa, Successfully Treated with Cemiplimab: A Case Report
by: Angelo Ruggiero, et al.
Published: (2023-02-01)

Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer
by: Ying-tao Lin, et al.
Published: (2024-01-01)

Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China
by: Huiqin Liu, et al.
Published: (2022-12-01)

Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China
by: Hongbin Dai, et al.
Published: (2023-02-01)

Rapid response to cemiplimab for advanced cutaneous squamous cell carcinoma
by: Hanieh Zargham, MD, et al.
Published: (2022-08-01)

Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside
by: D.T. Goodman
Published: (2022-09-01)

Can Cemiplimab Become a Life-Changer in Xeroderma Pigmentosum?
by: Maria Boziou, et al.
Published: (2023-07-01)

Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China
by: Mengdie Zhang, et al.
Published: (2023-05-01)

A Retrospective Study of Cemiplimab Effectiveness in Elderly Patients with Squamous Cell Carcinoma of the Skin: Insights from a Real-Life Scenario
by: Giuseppe Di Lorenzo, et al.
Published: (2023-12-01)

Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer
by: Maojin You, et al.
Published: (2022-10-01)

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer
by: Yitian Lang, et al.
Published: (2023-04-01)

IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab
by: Domenico Mallardo, et al.
Published: (2023-02-01)

Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
by: Xiaoyan Liu, et al.
Published: (2022-08-01)

Pharmacoeconomic evaluation of drug supply for chemotherapy in small cell lung cancer
by: Yelena A. Lunyova
Published: (2023-07-01)

Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients
by: T. Van Meerhaeghe, et al.
Published: (2022-10-01)

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma
by: Maojin You, et al.
Published: (2022-12-01)

The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy
by: Tae-Jun Jeong, et al.
Published: (2022-12-01)

Corrigendum: Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients
by: T. Van Meerhaeghe, et al.
Published: (2023-01-01)

The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
by: Brazel D, et al.
Published: (2023-06-01)

Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
by: Xueyan Liang, et al.
Published: (2023-08-01)

Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report
by: Anna Passarelli, et al.
Published: (2023-12-01)

Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection
by: Yuanyuan Yu, et al.
Published: (2021-05-01)

Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center
by: Nerina Denaro, et al.
Published: (2023-09-01)

Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression
by: Chuan Zhang, et al.
Published: (2023-03-01)